Best for
All-rounder

Updated
Ayala Pharmaceuticals, Inc (AYLA) is a leading biotechnology business based in the US. It opened the day at $12.29 after a previous close of $12.21. During the day the price has varied from a low of $11.7 to a high of $12.4. The latest price was $12.14 (25 minute delay). Ayala Pharmaceuticals is listed on the NASDAQ and employs 31 staff. All prices are listed in US Dollars.
Best for
All-rounder
Best for
Low-cost trading
Best for
US shares
Best for
Beginners
Open | $12.29 |
---|---|
High | $12.4 |
Low | $11.7 |
Close | $12.14 |
Previous close | $12.21 |
Change | $-0.07 |
Change % | -0.573% |
Volume | 5,121 |
52-week range | $8.62 - $16.5 |
---|---|
50-day moving average | $10.8721 |
200-day moving average | $11.6628 |
Wall St. target price | $21.6 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | N/A |
Other fees may apply. Your capital is at risk.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of $12.14
1 week (2021-01-08) | -3.68% |
---|---|
1 month (2020-12-18) | 5.11% |
3 months (2020-10-16) | -7.68% |
6 months (2020-07-17) | -2.88% |
Revenue TTM | $3.1 million |
---|---|
Gross profit TTM | $1 million |
Return on assets TTM | -46.93% |
Return on equity TTM | 0% |
Profit margin | 0% |
Market capitalisation | $150.1 million |
TTM: trailing 12 months
There are currently 15,707 Ayala Pharmaceuticals shares held short by investors – that's known as Ayala Pharmaceuticals's "short interest". This figure is 23.9% up from 12,678 last month.
There are a few different ways that this level of interest in shorting Ayala Pharmaceuticals shares can be evaluated.
Ayala Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ayala Pharmaceuticals shares currently shorted divided by the average quantity of Ayala Pharmaceuticals shares traded daily (recently around 16027.551020408). Ayala Pharmaceuticals's SIR currently stands at 0.98. In other words for every 100,000 Ayala Pharmaceuticals shares traded daily on the market, roughly 980 shares are currently held short.
However Ayala Pharmaceuticals's short interest can also be evaluated against the total number of tradable Ayala Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ayala Pharmaceuticals's short interest could be expressed as 0.0025% of the tradable shares (for every 100,000 tradable Ayala Pharmaceuticals shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ayala Pharmaceuticals.
Find out more about how you can short Ayala Pharmaceuticals stock.
We're not expecting Ayala Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Subscribe to trending stock alerts for a chance to win
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.
Find the cheapest and easiest ways to invest in Asia’s oldest stock exchange.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Find out the cheapest way to buy shares on Asia’s largest stock exchange.
Here’s the cheapest and easiest ways to invest in the world’s 4th-largest stock exchange.
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.